教师主页移动版

主页 > 广东省 > 暨南大学

吴晓萍

姓名 吴晓萍
性别
学校 暨南大学
部门 生命科学技术学院
学位 研究员
学历 生命科学技术学院
职称 研究员
联系方式 实用新型1875包写包过
邮箱 twxp@jnu.edu.cn
   
集群智慧云企服 / 知识产权申请大平台
微信客服在线:543646
急速申请 包写包过 办事快、准、稳
软件产品登记测试
软件著作权666元代写全部资料
实用新型专利1875代写全部资料

导航 个人简介 学习经历 工作经历 研究方向 主要论文 主要著作 承担课题,个人信息 姓名: 吴晓萍 部门: 生命科学技术学院 直属机构: 免疫生物学系 性别: 女 职务: 510632 职称: 研究员 学位: 博士 毕业院校: 暨南大学 联系电话: 85220732 电子邮箱: twxp@jnu.edu.cn 办公地址: 生命科学技术学院615室 通讯地址: 广州市天河区暨南大学生命科学技术学院6楼615 邮编: 510632 荣誉奖励: 省级青年人才 联系方式 个人简介 吴晓萍,暨南大学生命科学技术学院免疫生物学系研究员,生物医药博士生导师,免疫学硕士生导师。从事细胞因子与创伤修复、肿瘤的基础理论、临床应用及其相关基因工程药物的研发,主要涉及成纤维细胞生长因子(FGFs)家族的结构与功能关系、细胞效应与分子调控机制、FGFs规模化生产的关键技术、临床应用安全性等方面。成功研发了国家基因工程一类新药“重组人酸性成纤维细胞生长因子”。获国家科学技术发明二等奖、广东省科学技术发明一等奖、中华医学科技奖一等奖、中国药学科学技术一等奖和中国专利优秀奖等奖项共5项。主持或参与国家自然科学基金重点项目、国家863计划项目、国家重大生物医药专项、国家自然科学基金面上项目、省自然科学基金和省科技计划项目等各级项目17项,发表SCI论文46篇,获批发明专利3项,其中1项已实现产业化,产生了良好的社会和经济效益。参编著作3部(2部为副主编)。入选广东省千百十工程省级人才。担任国家基金委创新群体、国家自然科学基金、广东省自然科学基金、广东省科技计划项目等基金评审专家,教育部学位与研究生教育论文评审专家。先后任Breast Cancer Research、Applied Microbiology and Biotechnology、International Journal of Oncology等多种国际杂志审稿专家。 学习经历 2004.9~2007.6  暨南大学  生物医学工程专业  获理学博士学位1993.9~1996.6  中山大学  生物化学专业     获理学硕士学位1989.9~1993.6  四川大学  生物化学专业     获理学学士学位 工作经历 2011~2012  Texas A&M Health Science Center,访问学者2006~至今  暨南大学组织移植与免疫研究中心/免疫生物学系,研究员,博导1999~2006  暨南大学医药生物技术研究开发中心,副研究员1996~1999  广东省生物资源应用研究所,研究实习员 主要论文 [1] Wu Luo, Xiaomian Lin, Tianxiang Wang, Jialong Cai, Xiangfeng Zeng, Cairong Zhu, Rongzhen Li, Heng Wang, Xiaoping Wu*. Identification of a crucial amino acid responsible for the loss of specifying FGFR1–KLB affinity of the iodinated FGF21. J Cell Physiol. 2019, 234(3): 2500-2510.[2] Hongjiao Liu, Xiaomian Lin, Tao Huang, Li Song, Cairong Zhu*, Hongmin Ma, Tianzhu Long, Huixuan Zeng, Rongzhen Li, Heng Wang, Yishan Huang, Liankuai Chen, Xiaoping Wu*. A short peptide reverses the aggressive phenotype of prostate cancer cells. Eur J Pharmacol. 2018, 838: 129-137.[3] Jianzhang Wu, Shoubiao Wu, Lingyi Shi, Shanshan Zhang, Jiye Ren, Song Yao, Di Yun, Lili Huang, Jiabing Wang, Wulan Li*, Xiaoping Wu*, Peihong Qiu, Guang Liang*. Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anti-cancer agents for lung cancer. Eur J Med Chem. 2017, 125: 1321-1331.[4] Xiaomian Lin, Li Song, Dan He, Xiangfeng Zeng, Jianzhang Wu, Wu Luo, Qi Yang, Jizhong Wang, Wang Tianxiang, Cai Jialong, Lin Yanling, Lai Fubin, Peng Wentao, Xiaoping Wu*. An FGF8b-mimicking peptide with potent antiangiogenic activity. Mol Med Rep. 2017, 16(1): 894-900.[5]Jizhong Wang, Xiangpeng Tan, Qi Yang, Xiangfeng Zeng, Yuying Zhou, Wu Luo, Xiaomian Lin, Li Song, Jialong Cai, Tianxiang Wang, Xiaoping Wu*. Inhibition of autophagy promotes apoptosis and enhances anticancer efficacy of adriamycin via augmented ROS generation in prostate cancer cells. Int J Biochem Cell Biol. 2016, 77(Pt A): 80-90.[6] Tao Huang, Xiaomian Lin, Quchou Li, Wu Luo, Li Song, Xiangpeng Tan, Wenhui Wang, Xiaokun Li, Xiaoping Wu*. Selection of a novel FGF23-binding peptide antagonizing the inhibitory effect of FGF23 on phosphate uptake. Appl Microbiol and Biotechnol. 2015, 99(7): 3169-3177. [7] Wu Luo, Yonglin Yu, Ruixue Wang, Dan He, Cong Wang, Xiangfeng Zeng, Xilei Chen, Xiangpeng Tan, Tao Huang, Xiaoping Wu*. P7 peptides targeting bFGF sensitize colorectal cancer cells to CPT-11. Int J Mol Med. 2014, 33(1): 194-200.[8] Xiangpeng Tan, Xilei Chen, Tao Huang, Wu Luo, Dan He, Xiaomian Lin, Li Song, Xiaoping Wu*. Mechanism of bFGF-binding Peptide Reversing Adriamycin Resistance in Human Gastric Cancer Cells. Int J Pept Res Ther. 2014, 20(4): 427–434.[9] Wenhui Wang, Xilei Chen, Tao Li, Yanmei Li, Ruixue Wang, Dan He, Wu Luo, Xiaokun Li, Xiaoping Wu*. Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer. Exp Cell Res. 2013, 319(8): 1156-1164.[10] Tao Li, Wu Luo, Dan He, Ruixue Wang, Yadong Huang, Xiangfeng Zeng, Wenhui Wang, Xilei Chen, Susu Gao, Yonglin Yu, Xiaokun Li, Xiaoping Wu*. A short peptide derived from the gN helix domain of FGF8b suppresses the growth of human prostate cancer cells. Cancer Lett. 2013, 339(2): 226-236.[11] Ruixue Wang, Wu Luo, Xiangfeng Zeng, Jingfang Di, Yonglin Yu, Chuan Wang, Wenhui Wang, Xilei Chen, Dan He, Tao Li, Xiaoping Wu*. A bFGF Antagonist Peptide with Anti-angiogenesis Properties in Non-small Cell Lung Cancer Cells. Int J Pept Res Ther. 2013, 19(3): 295-302. [12] Yonglin Yu, Susu Gao, Quchou Li, Cong Wang, Xinqiang Lai, Xilei Chen, Ruixue Wang, Jingfang Di , Tao Li, Wenhui Wang, Xiaoping Wu*. The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo. J Cancer Res Clin Oncol. 2012, 138:1321–1328. [13] Susu Gao, Yonglin Yu, Xinqiang Lai, Tao Li, Quchou Li, Xilei Chen, Ruixue Wang, Wenhui Wang, Xiaoping Wu*. Anti-Proliferation Effect of a Short Peptide on bFGF-Induced Human Gastric Cancer Cells. Int J Pept Res Ther. 2012, 18 (4): 299-304. [14] Quchou Li, Susu Gao, Yonglin Yu, Wenhui Wang, Xilei Chen, Ruixue Wang, Tao Li, Cong Wang, Xiaokun Li, Xiaoping Wu*. A novel bFGF antagonist peptide inhibits breast cancer cell growth. Mol Med Report. 2012, 6(1): 210-214. [15] Xiaoping Wu#, Qiuxia Yan#, Yadong Huang#, Huixian Huang, Zhijian Su, Jian Xiao, Yaoying Zeng, Yi Wang, Changjun Nie, Yongguang Yang*, Xiaokun Li*. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med. 2010, 14(1-2): 351-356. [16] Cong Wang, Shaoqiang Lin, Yanfang Nie, Xinglong Jia, Jing Wang, Jian Xiao, Jianzhang Wu, Xiaokun Li*, Xiaoping Wu*. Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Sci. 2010. 101(5): 1212-1218.[17] Xiaoping Wu#, Haishan Tian#, Yadong Huang, Sixian Wu, Xiaoju Liu, Cong Wang, Xiaojie Wang, Zhifeng Huang, Jian Xiao, Wenke Feng, Xiaokun Li*. Large-scale production of biologically active human keratinocyte growth factor-2. Appl Microbiol Biotechnol. 2009, 82(3): 439-444. [18] Xiaoping Wu#, Changjun Nie#, Zhifeng Huang, Yanfang Nie, Qiuxia Yan, Yecheng Xiao, Zhijian Su, Yadong Huang, Jian Xiao, Yaoying Zeng, Yi Tan, Wenke Feng*, Xiaokun Li*. Expression and Purification of Human Keratinocyte Growth Factor 2 by Fusion with SUMO. Mol Biotechnol. 2009, 42(1): 68-74.[19] Xiaoping Wu#, Xiaoju Liu#, Yecheng Xiao, Zhifeng Huang, Jian Xiao, Shaoqiang Lin, Lu Cai, Wenke Feng*, Xiaokun Li*. Purification and modification by polyethylene glycol of a new human basic fibroblast growth factor mutant-hbFGFSer25,87,92. J Chromatogr A, 2007,1161(1-2): 51-55. [20] Xiaokun Li, Lijuan

    本企业已通过ISO9001国际质量管理体系认证
    ISO45001职业健康安全管理体系认证
    ISO14001环境管理体系认证
    企业信用等级AAA级认证
    科技型中小企业认证、高新技术企业认证。
    增值电信业务经营(ICP/EDI)许可证:辽B2-20230179
    版权所有:集群智慧(大连)信息技术有限公司
    ICP备案:辽ICP备2022010488号-9